Publication
2nd Circuit defers to executive will on application of sovereign immunity
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
Canada | Publication | October 2023
Norton Rose Fulbright lawyers Kristin Wall, Randy Sutton, Veronique Barry, Christopher Guerreiro and Sarah Pennington contributed the Canada chapters to the Practical Law Life Sciences Global Guide on commercialization and regulation. The Guide is published in a Q&A format by Thomson Reuters, which is a leading global platform for trusted, up-to-date legal know how across all major practice areas.
Life Sciences Commercialisation in Canada: Overview
The Q&A Guide to life sciences commercialisation in Canada provides an overview of Canada’s life sciences sector, pricing and state funding, distribution and sale, importing, advertising, patents, trade marks, competition law, and product liability.
Life Sciences Regulation in Canada: Overview
The Q&A guide to life sciences regulation in Canada reviews the main legislation governing pharmaceuticals in Canada. The guide provides an overview of key practical issues, including clinical trials, manufacturing, marketing, abridged procedures, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, and natural health products.
Publication
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
Publication
Facing the fast-growing development of AI across the globe, particularly Generative AI (GenAI), the G7 competition authorities and policymakers (Canada, France, Germany, Japan, Italy, the UK and the US) and the European Commission met in Italy on 3-4 October 2024 to discuss the main competition challenges raised by these new technologies in digital markets.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023